Current Investments

1

NAPEC

NAPEC is a leading provider of construction and maintenance services to the utility and heavy industrial markets across North America. The Company builds and maintains utility electrical and natural gas transmission and distribution systems and related energy infrastructure including substations. NAPEC also installs generation and other heavy equipment for utilities, industrial plants, and petrochemical facilities. The Company’s construction services also include environmental, renewable, and civil construction and road matting services. https://riggsdistler.com

TurnCare

TurnCare is an early commercial stage medical device company that has developed a unique, patented non-invasive technology that helps protect and manage high acuity patients. TurnCare’s Guardian System is being used in acute care to manage patients that are both difficult to turn and at high risk of pressure injuries. Examples include mechanically and non-mechanically ventilated sepsis, cardiogenic shock, trauma, and respiratory failure critical care patients. Clinicians are looking to the Company’s Guardian System for help to mobilize these patients faster, with fewer skin injuries and less clinical effort. https://www.turncare.com

2

TRS II

TRS II

TRS II is an early stage medical technology company that has patented and patent-pending technology capable of producing a transdermal patch that delivers approximately 1,200 IU’s of Vitamin D3 through the skin and into the bloodstream on a daily basis, avoiding the gastrointestinal tract.

The Company's delivery system allows the absorption of Vitamin D3 by individuals, known as chronic mal-absorbers, who cannot or have difficulty absorbing orally ingested Vitamin D supplements, including individuals with cystic fibrosis, bariatric surgery patients, osteoporosis patients, and various gastro-intestinal disorders. The Company believes that is no other product available on the market today that delivers Vitamin D3 transdermally.

TRS II

TRS II

TRS II is an early stage medical technology company that has patented and patent-pending technology capable of producing a transdermal patch that delivers approximately 1,200 IU’s of Vitamin D3 through the skin and into the bloodstream on a daily basis, avoiding the gastrointestinal tract.

The Company's delivery system allows the absorption of Vitamin D3 by individuals, known as chronic mal-absorbers, who cannot or have difficulty absorbing orally ingested Vitamin D supplements, including individuals with cystic fibrosis, bariatric surgery patients, osteoporosis patients, and various gastro-intestinal disorders. The Company believes that is no other product available on the market today that delivers Vitamin D3 transdermally.